Noncontrolling Interest (Tables)

3 Months Ended

Mar. 31, 2022

Noncontrolling Interest [Abstract]

Schedule of Noncontrolling Interest of Stockholders' Equity

The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity is summarized for the periods indicated as follows:

	March 31, 2022			December 31, 2021
NCI – equity (deficit) – beginning of period	$	17,752		$	(2,369	)
Investment in Veris Health Inc.		—			6
Net loss attributable to NCI		(2,761	)		(5,779	)
Impact of subsidiary equity transactions		87			16,760
Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise		187			—
Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan		3,537			9,134
NCI – equity (deficit) – end of period	$	18,802		$	17,752